Downloading...
Download

Fasttrack

AYTU All Time Low | Fast Track Designation form FDA todayAYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome. After the bullish news, AYTU stock hit the all time low level. 52 Week Range 0.76 - 7.20 LADENBURG THALM has a price target of $14.50 for the stock. I think a reversal is imminent. My price target is $5.25. Looking forward to read your opinion about it.
NASDAQ:AYTULong
by TopgOptions
1
MBRX Annamycin Fast Track and Orphan Drug Designation from FDAMoleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases. the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. This should be an interesting year for MBRX, which is at all time low now. 52 Week Range 1.64 - 8.78 My price target is $3.8
NASDAQ:MBRXLong
by TopgOptions
ACXP cheaper than the public offeringAcurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat and in the second half of 2021. (prnewswire.com)
NASDAQ:ACXPLong
by TopgOptions